Indeed, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) provided the first proof of the contribution of inflammation to atherosclerosis in humans and demonstrated that neutralizing interleukin-1 beta (IL-1β) reduces cardiovascular events in patients with atherosclerosis and prior MI (5, 6). This evidence concerns the gene IL1B and atherosclerosis.